Safely treat canine osteoarthritis (OA) from its earliest diagnosed stages

Galliprant® (grapiprant tablets) is a first-in-class prostaglandin receptor antagonist (PRA), a non-COX inhibiting NSAID. It specifically targets the EP4 receptor, the primary mediator of canine OA pain and inflammation.1 Treatment can be started in dogs as early as 9 months of age.

  • Galliprant does not inhibit the production of many housekeeping prostanoids that maintain homeostatic functions1,2
  • It specifically blocks the EP4 receptor, the primary mediator of canine OA pain and inflammation1

Galliprant – a mode of action unlike any other

Proven effective3

Galliprant treatment resulted in statistically significant improvements in pain interference and pain severity scores compared to placebo on days 7, 14, 21 and 28*.3

  • Prospective, randomized, masked, placebo-controlled, 16-site study
  • Galliprant dosed at 2mg/kg once daily for 28 days
  • 285 dogs enrolled
  • Dogs receiving Galliprant were 2 to 16.75 years old, weighing 9 to 131 pounds
  • Placebo tablet size and shape matched to Galliprant tablets
  • Validated owner assessment: Canine Brief Pain Inventory (CBPI)** on days 0, 7, 14, 21, 28
  • Veterinary assessment (total orthopedic scores) at screening and on days 14 and 28

* Primary study endpoint

** The CBPI is a validated questionnaire that asks dog owners four questions about the severity of pain evident in a dog (the pain severity score) and six questions about how pain interferes with a dog’s activity level (the pain interference score). The questionnaire also has one overall impression score and is useful in detecting changes in a dog’s condition that result from intervention (e.g., medication, surgery).

Grapiprant represents a promising treatment modality for the pain and inflammation associated with OA in dogs.3

Please see important safety information below.

Most dogs can be dosed once a day with a whole or half tablet

†Dosage should be calculated in half-tablet increments. Dogs weighing less than 8 lbs (3.6 kg) cannot be accurately dosed.

Treat with Galliprant from the earliest diagnosed stages of canine OA

Mode of action targets canine OA pain and inflammation while reducing the impact on GI, kidney and liver homeostasis1,2.

  • Suitable for dogs as young as 9 months of age
  • Most dogs can be dosed with a whole or half tablet

Please see important safety information below.

Incorporate Galliprant into your canine OA pain protocol today
For more information, contact your Elanco, Aratana or distributor representative.

Indication

Galliprant is indicated for the control of pain and inflammation associated with osteoarthritis in dogs.

Important Safety Information

Not for use in humans. For use in dogs only. Keep this and all medications out of reach of children and pets. Store out of reach of dogs and other pets in a secured location in order to prevent accidental ingestion or overdose. Do not use in dogs that have a hypersensitivity to grapiprant. If Galliprant is used long term, appropriate monitoring is recommended. Concomitant use of Galliprant with other anti-inflammatory drugs, such as COX-inhibiting NSAIDs or corticosteroids, should be avoided. Concurrent use with other anti-inflammatory drugs or protein-bound drugs has not been studied. The safe use of Galliprant has not been evaluated in dogs younger than 9 months of age and less than 8 lbs (3.6 kg), dogs used for breeding, pregnant or lactating dogs, or dogs with cardiac disease. The most common adverse reactions were vomiting, diarrhea, decreased appetite, and lethargy. Click here for full prescribing information.